• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Absci Corporation

    2/13/24 6:16:38 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $ABSI alert in real time by email
    SC 13G 1 schedule13gseanmcclain0213.htm SC 13G Document



    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

    Absci Corporation

    (Name of Issuer)

    Common Stock, par value, $0.0001 per share

    (Title of Class of Securities)

    00091E109

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    ☐ Rule 13d-1(b)
    ☐ Rule 13d-1(c)
    x Rule 13d-1(d)


    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).













    CUSIP No. 00091E109




    1.Names of Reporting Person:
    Sean McClain
    2Check the Appropriate Box if a Member of a Group:
    (a) ☐ (b) ☐
    3. SEC Use Only:
    4.Citizenship or Place of Organization:
    United States
    Number of5.Sole Voting Power:
    Shares9,373,113(1)
    Beneficially
    6.
    Shared Voting Power:
    Owned by0
    Each7.Sole Dispositive Power:
    Reporting7,093,577(2)
    Person8Shared Dispositive Power:
    With:0
    9.Aggregate Amount Beneficially Owned by Each Reporting Person:
    9,373,113(1)
    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares:
    ☐
    11.Percent of Class Represented by Amount in Row (9):
    10.0%(3)
    12.Type of Reporting Person:
    IN

    (1)Consists of (i) 6,368,955 shares of common stock held of record by Sean McClain (the “Reporting Person”), (ii) 2,269,987 shares of common stock held by Brittany McClain, which shares are subject to a voting agreement and proxy pursuant to which the Reporting Person is entitled to vote such shares on all matters presented to the Issuer’s stockholders for approval, (iii) 724,622 shares of common stock subject to options exercisable by the Reporting Person within 60 days of December 31, 2023, and (iv) 9,549 shares of common stock subject to options exercisable by Brittany McClain within 60 days of December 31, 2023, which are subject to a voting agreement proxy pursuant to which the Reporting Person is entitled to vote such shares on all matters presented to the Issuer’s stockholders for approval.
    (2)Consists of (i) 6,368,955 shares of common stock held of record by the Reporting Person and (ii) 724,622 shares of common stock subject to options exercisable within 60 days of December 31, 2023.
    (3)Based on the quotient obtained by dividing (a) the aggregate amount beneficially owned by the Reporting Person as set forth in Row 9 by (b) the sum of (i) 93,087,675 shares of common stock outstanding as of December 31, 2023 and (ii) 734,171 shares of common stock subject to options exercisable within 60 days of December 31, 2023.




    CUSIP No. 00091E109





    ITEM 1.

    (a)Name of Issuer: Absci Corporation

    (b)Address of Issuer’s Principal Executive Offices:
    18105 SE Mill Plain Boulevard
    Vancouver, WA 98683

    ITEM 2.

    (a)Name of Person Filing: Sean McClain

    (b)Address of Principal Business Office, or if None, Residence:

    c/o Absci Corporation

    18105 SE Mill Plain Boulevard Vancouver, WA 98683

    (c)Citizenship: United States
    (d)Title of Class of Securities:

    Common stock, par value, $0.0001 per share

    (e)CUSIP Number: 00091E109

    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SS.240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

    (a)☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

    (b)☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);

    (c)☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);

    (d)☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a— 8);

    (e)☐ An investment adviser in accordance with §240.13d—1(b)(1)(ii)(E);

    (f)☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

    (g)☐ A parent holding company or control person in accordance with §240.13d—1(b)(1)(ii)(G);

    (h)☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

    (i)☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company

    Act of 1940 (15 U.S.C. 80a-3);

    (j)☐ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J)

    (k)☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

    Not Applicable.


    ITEM 4. OWNERSHIP.

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a)Amount beneficially owned:
    9,373,113
    (b)Percent of Class:
    10.0%(b) ☐
    (c)Number of Shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 9,373,113(1)
    (ii) Shared power to vote or to direct the vote: 0
    (iii) Sole power to dispose or to direct the disposition of: 7,093,577(2)
    (iv) Shared power to dispose or to direct the disposition of: 0

    (1)Consists of (i) 6,368,955 shares of common stock held of record by Sean McClain (the “Reporting Person”), (ii) 2,269,987 shares of common stock held by Brittany McClain, which shares are subject to a voting agreement and proxy pursuant to which the Reporting Person is entitled to vote such shares on all matters presented to the Issuer’s stockholders for approval, (iii) 724,622 shares of common stock subject to options exercisable by the Reporting Person within 60 days of December 31, 2023, and (iv) 9,549 shares of common stock subject to options exercisable by Brittany McClain within 60 days of December 31, 2023, which are subject to a voting agreement proxy pursuant to which the Reporting Person is entitled to vote such shares on all matters presented to the Issuer’s stockholders for approval.
    (2)Consists of (i) 6,368,955 shares of common stock held of record by the Reporting Person and (ii) 724,622 shares of common stock subject to options exercisable within 60 days of December 31, 2023.





    CUSIP No. 00091E109




    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

    Not applicable.

    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

    Not applicable.

    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.

    Not applicable.

    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

    Not applicable.

    ITEM 9. NOTICE OF DISSOLUTION OF GROUP.

    Not applicable.

    ITEM 10. CERTIFICATIONS.

    Not applicable.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 13, 2024/s/ Todd Bedrick
    Todd Bedrick, Attorney-in-fact for Sean McClain


    Get the next $ABSI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABSI

    DatePrice TargetRatingAnalyst
    7/3/2025$7.00Overweight
    Morgan Stanley
    1/22/2025$9.00Buy
    Needham
    10/2/2024$10.00Buy
    Guggenheim
    7/3/2024$7.00Overweight
    Morgan Stanley
    3/14/2024$13.00Sector Outperform
    Scotiabank
    12/5/2023$3.00Overweight
    KeyBanc Capital Markets
    5/4/2023$4.00Buy
    H.C. Wainwright
    8/12/2022Overweight → Underweight
    JP Morgan
    More analyst ratings

    $ABSI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Innovation Officer Busch Andreas bought $152,000 worth of shares (50,000 units at $3.04), increasing direct ownership by 18% to 327,264 units (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    7/29/25 8:37:44 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Redmile Group, Llc bought $999,999 worth of shares (222,222 units at $4.50) (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    3/5/24 9:30:43 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Innovation Officer Busch Andreas bought $152,000 worth of shares (50,000 units at $3.04), increasing direct ownership by 18% to 327,264 units (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    7/29/25 8:37:44 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 4 filed by Director Szela Mary T

    4 - Absci Corp (0001672688) (Issuer)

    7/9/25 4:46:43 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 3 filed by new insider Szela Mary T

    3 - Absci Corp (0001672688) (Issuer)

    7/9/25 4:43:26 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Absci Reports Business Updates and Second Quarter 2025 Financial and Operating Results

    Strengthened balance sheet raising approximately $64 million in gross proceeds in July 2025; cash, cash equivalents, and short-term investments now sufficient to fund operations into the first half of 2028 Expanded ongoing collaboration with Almirall, with election of a second target focused on dermatological indications VANCOUVER, Wash. and NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today reported financial and operating results for the quarter ended June 30, 2025. "The past few months have been a period of strong execution for Absci, and we are positione

    8/12/25 4:05:00 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target

    Almirall selects second target in AI Drug Creation collaborationExpanded collaboration builds on Absci's successful de novo molecule design for difficult‑to‑drug targets in the first stage of the collaboration with Almirall BARCELONA, Spain and VANCOUVER, Wash., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Almirall (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced the expansion of their ongoing AI Drug Discovery collaboration with Almirall's selection of a second target aimed at dermatological indications. The expansion

    8/7/25 2:00:00 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Absci to Report Business Updates and Second Quarter 2025 Financial and Operating Results on August 12, 2025

    VANCOUVER, Wash. and NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design, today announced the company will report business updates and financial and operating results for the second quarter 2025 after market close on Tuesday, August 12, 2025. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company's investor relations website at: investors.absci.com. The we

    7/30/25 4:05:00 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley resumed coverage on Absci Corporation with a new price target

    Morgan Stanley resumed coverage of Absci Corporation with a rating of Overweight and set a new price target of $7.00

    7/3/25 7:48:59 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Needham initiated coverage on Absci Corporation with a new price target

    Needham initiated coverage of Absci Corporation with a rating of Buy and set a new price target of $9.00

    1/22/25 7:30:02 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Guggenheim initiated coverage on Absci Corporation with a new price target

    Guggenheim initiated coverage of Absci Corporation with a rating of Buy and set a new price target of $10.00

    10/2/24 7:13:36 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Absci Corporation

    SC 13G - Absci Corp (0001672688) (Subject)

    11/14/24 4:02:50 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form SC 13G/A filed by Absci Corporation

    SC 13G/A - Absci Corp (0001672688) (Subject)

    11/12/24 9:50:12 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13D/A filed by Absci Corporation (Amendment)

    SC 13D/A - Absci Corp (0001672688) (Subject)

    3/5/24 5:15:30 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    Leadership Updates

    Live Leadership Updates

    View All

    Absci Appoints Biopharma Leader Mary Szela to Board of Directors

    VANCOUVER, Wash., July 07, 2025 (GLOBE NEWSWIRE) -- Absci (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the appointment of veteran biopharmaceutical executive Mary Szela to its Board of Directors. With decades of R&D and commercial leadership experience, Ms. Szela has played pivotal roles in advancing transformative therapies, notably guiding the global launch and expansion of Humira® into multiple indications during her tenure at Abbott Laboratories. "Mary has been a driving force behind the development of one of the most successful therapies in the industry, bringing a rare and invaluable bread

    7/7/25 8:00:00 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Absci Appoints Professor Sir Mene Pangalos to its Board of Directors

    Sir Pangalos is a distinguished biopharmaceutical executive who led BioPharmaceuticals R&D at AstraZeneca.  In addition to joining Absci's Board, Sir Pangalos will co-chair Absci's Scientific Advisory Board. VANCOUVER, Wash., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Absci (NASDAQ:ABSI), a generative AI drug creation company, today announced the appointment of seasoned R&D executive Professor Sir Menelas "Mene" Pangalos to its Board of Directors and as co-chair of Absci's Scientific Advisory Board. Sir Pangalos was the Executive Vice President of BioPharmaceuticals R&D at AstraZeneca. He joins Absci as the company scales its AI-enabled portfolio of partnered and wholly-owned assets. "The rapid e

    1/10/24 7:30:00 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Absci Evolves its Board of Directors with HealthTech Luminary Frans van Houten, Former CEO of Philips

    VANCOUVER, Wash., June 06, 2023 (GLOBE NEWSWIRE) -- Absci (NASDAQ:ABSI), a generative AI drug creation company, today announced the appointment of Frans van Houten to its Board of Directors. With his exceptional leadership experience and deep industry knowledge in the healthcare and technology industries, van Houten will play a pivotal role in supporting Absci's strategic vision and growth trajectory. Frans van Houten is a highly regarded business executive with a remarkable track record of success. During his tenure as CEO of Royal Philips, van Houten led the company's transformation into a global leader in health technology, overseeing a critical strategic transformation, resulting in a

    6/6/23 8:00:00 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    SEC Filings

    View All

    Amendment: Absci Corporation filed SEC Form 8-K: Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

    8-K/A - Absci Corp (0001672688) (Filer)

    8/12/25 5:10:10 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form S-3 filed by Absci Corporation

    S-3 - Absci Corp (0001672688) (Filer)

    8/12/25 5:06:47 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 10-Q filed by Absci Corporation

    10-Q - Absci Corp (0001672688) (Filer)

    8/12/25 4:45:49 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    Financials

    Live finance-specific insights

    View All

    Absci to Report Business Updates and Second Quarter 2025 Financial and Operating Results on August 12, 2025

    VANCOUVER, Wash. and NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design, today announced the company will report business updates and financial and operating results for the second quarter 2025 after market close on Tuesday, August 12, 2025. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company's investor relations website at: investors.absci.com. The we

    7/30/25 4:05:00 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Absci Reports Business Updates and First Quarter 2025 Financial and Operating Results

    Initiated dosing of participants in the first-in-human study of ABS-101 (anti-TL1A antibody), with interim data expected in the second half of 2025 ABS-201 (anti-PRLR) non-human primate (NHP) data demonstrate extended half life and high subcutaneous bioavailability; anticipate Phase 1 initiation in early 2026 Cash, cash equivalents, and short-term investments sufficient to fund operations into the first half of 2027 VANCOUVER, Wash. and NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design, today reported financial and operating results for the qu

    5/13/25 4:05:00 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 2025

    VANCOUVER, Wash. and NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the first quarter 2025 after market close on Tuesday, May 13, 2025. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company's investor relations website at: investors.absci.com. The webcast will be archived and available for replay after th

    4/14/25 4:05:00 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care